Sevelamer
- Generic Name
- Sevelamer
- Brand Names
- Renagel, Renvela, Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12ClNO
- CAS Number
- 52757-95-6
- Unique Ingredient Identifier
- 941N5DUU5C
Overview
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Background
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
Associated Conditions
- Hyperphosphataemia
Clinical Trials
FDA Approved Products
sevelamer hydrochloride
Manufacturer:NorthStar RxLLC
Route:ORAL
Strength:800 mg in 1 1
Approved: 2023/05/24
NDC:72603-148
Sevelamer Carbonate
Manufacturer:Marlex Pharmaceuticals Inc
Route:ORAL
Strength:800 mg in 1 1
Approved: 2018/05/10
NDC:10135-660
Sevelamer Carbonate
Manufacturer:Bionpharma Inc.
Route:ORAL
Strength:800 mg in 1 1
Approved: 2021/11/03
NDC:69452-126
Sevelamer carbonate
Manufacturer:Rising Pharmaceuticals, Inc.
Route:ORAL
Strength:800 mg in 1 1
Approved: 2022/10/18
NDC:16571-739
SEVELAMER CARBONATE
Manufacturer:Strides Pharma Science Limited
Route:ORAL
Strength:2400 mg in 2790 mg
Approved: 2024/02/23
NDC:64380-881
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath